Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Athenex, Inc. clinical trials
Also known as Kinex Pharmaceuticals.
The registry lists 23 studies whose lead sponsor is Athenex, Inc.. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated May 22, 2023.
Keep track of what changes. Save the Athenex, Inc. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Athenex, Inc..
- Athenex, Inc.21 studiesSame company
Something wrong?
- Kinex Pharmaceuticals Inc.2 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 23 of 23.
- Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell MalignanciesRecruitingNCT05487651Phase 1
- The Effect of Food on the Pharmacokinetics of Paclitaxel Administered Orally as OraxolTerminatedNCT03892018Phase 1
- A Study of Oraxol in Subjects With Cutaneous AngiosarcomaCompletedNCT03544567Phase 2
- Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid TumorsTerminatedNCT03588039Phase 1
- Safety and Efficacy Study of KX2-391 for Treatment of Bone-Metastatic, Castration-Resistant Prostate CancerCompletedNCT01074138Phase 2
- Evaluate TCRT-ESO-A2 Autologous T Cells Expressing TCR Specific for NY-ESO-1 in Subjects With Advanced Solid TumorsWithdrawnNCT04878484Phase 1
- Ph3 Study To Determine Safety,Tolerability&Tumor Response Of Oraxol Compared To Taxol In Metastatic Breast CancerCompletedNCT02594371Phase 3
- A Study to Determine the Bioequivalence of Oraxol in Cancer Patients Treated With Intravenous PaclitaxelCompletedNCT04035473Phase 1
- An Extension Study to Provide Oraxol to Patients Who Completed KX-ORAX-007TerminatedNCT04168957Phase 1
- A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced MalignanciesCompletedNCT02250157Phase 1
- Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal CancersStatus unknownNCT02970539Phase 1
- Evaluate Oral Topotecan With HM30181A Monotherapy in Patients With Advanced MalignanciesCompletedNCT03987685Phase 1
- A Study to Evaluate the Safety, Tolerability, MTD, PK, and Activity of Oraxol in Subjects w Adv. MalignanciesCompletedNCT02730481Phase 1
- A Phase I Open-label Study for Subjects With Advanced MalignanciesStatus unknownNCT04136834Phase 1
- A PK Study of Oraxol in Breast Cancer PatientsCompletedNCT04993040Phase 1
- A Safety Study of Oraxol (HM30181 + Oral Paclitaxel) in Cancer PatientsCompletedNCT04180384Phase 2
- Single-Center Study Evaluating Systemic Exposure and Safety of KX2-391 Ointment 1% on the Face or Balding Scalp in Subjects With Actinic KeratosisCompletedNCT03575780Phase 1
- A DRF Study to Evaluate Safety, Tolerability, PK, and Activity of Oradoxel Monotherapy in Subjects w Adv. MalignanciesStatus unknownNCT02963168Phase 1
- Safety, Tolerability & PK of KX2-361 in Subjects w Adv. Malignancies Refractory to Conventional TherapiesCompletedNCT02326441Phase 1
- Ph 1, Single-Center, Safety, Tolerability & Pharmacokinetic Study of KX2 391 Ointment in Subj. w Actinic KeratosisCompletedNCT02337205Phase 1
- A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oraxol in Subjects With Advanced MalignanciesCompletedNCT01967043Phase 1
Sponsor listed in the registry: Kinex Pharmaceuticals Inc.
- Evaluation of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia (AML)CompletedNCT01397799Phase 1
Sponsor listed in the registry: Kinex Pharmaceuticals Inc.
- Evaluation of KX2-391 in Patients With Advanced MalignanciesCompletedNCT00658970Phase 1